Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE (PAR: OSE) launches AI immunotherapy partnership
Published by Arron Aatkar, PhD

OSE has signed a strategic partnership with Scienta Lab, aiming to model inflammatory diseases and identify predictive biomarkers of efficacy for immunotherapies. Scienta Lab is a France-based leader in AI-driven precision immunology, and under this agreement, it will be employing its AI-powered multimodal foundation model dedicated to translational immunology research. Ultimately, OSE believes this partnership will support the development of tailored immunotherapies and drive more favourable outcomes for patients with immune-mediated inflammatory conditions.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free